PARSIPPANY, N.J., Sept. 7 /PRNewswire/ -- DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, today announced the launch of InnoSyn™ route scouting services. In response to the increasing interest of pharmaceutical customers to outsource the development of robust low-cost manufacturing routes, DSM is offering focused and flexible stand alone route scouting services. DSM's route scouting capabilities lead to significant cost savings by the reduction of synthesis steps or redesign of synthesis routes.
The InnoSyn™ route scouting team supports research and development, and the implementation of economical and scalable routes. Unique value creating solutions are provided by integrating the full range of enabling DSM competencies such as biocatalysis, homogeneous catalysis, organic synthesis and continuous chemistry using for example micro reactors. These capabilities to rapidly screen a wide variety of catalysts speed up feasibility studies for chemocatalytic and biocatalytic steps.
Recent success stories have introduced new efficient enzymes, such as pharmaPLE®, lyases, transaminases, dehydrogenases and new, easily accessible homogeneous catalysts for asymmetric hydrogenations, aromatic substitutions, and oxidations. Furthermore, a safe and clean nitration reaction was implemented under cGMP for manufacturing of an API based on DSM's micro reactor technology. InnoSyn™services are based in DSM's Geleen, The Netherlands R&D facilities and utilize DSM's wide range of technology and production sites across Europe.
Oliver May, Ph.D., Business Manager InnoSyn™ route scouting services commented, "DSM is recognized as a reliable and leading large scale cGMP manufacturer for registered intermediates and active pharmaceutical ingredients. This remains our focus but we also want to continuously serve changing customer needs whenever DSM can provide real value. Due to the reduced focus and resources in process R&D within our customers' operations there is an increasing demand for developing flexible and robust 'technology packages' ready to implement at large scale. The new DSM InnoSyn™ route scouting services are setup to address exactly this specific need based on DSM's broad and unique technology toolbox. Please visit us at CPhI Worldwide Oct 5-7 in Paris to learn more about the value we provide in this area."
Dr. May will be speaking at 13:00 PM on Tuesday, October 5th at the global CPhI Worldwide conference in Paris.
InnoSyn™ is a trademark of DSM
pharmaPLE® is a registered trademark of DSM
DSM Pharma Chemicals
DSM Pharma Chemicals is a global provider of custom manufacturing services to the pharmaceutical industry, including advanced intermediates, registered materials and active pharmaceutical ingredients. Our offerings include route scouting services, fermentation, organic synthesis, chiral technologies, and continuous chemistry using micro reactors. DSM delivers comprehensive custom manufacturing services to the spectrum of pharmaceutical companies including emerging pharmaceutical companies and large pharmaceutical companies from clinical to commercial manufacturing. More information: www.dsmpharmachemicals.com
DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticalproducts.com
DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com
DSM Forward-looking statements
This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and information currently available. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that their expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.
SOURCE DSM Pharmaceutical Products